Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2009
At a glance
- Drugs Lonafarnib (Primary)
- Indications Brain cancer
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 20 Oct 2009 Actual patient number (53) added as reported by ClinicalTrials.gov.
- 21 Aug 2007 Status change from in progress to completed.